Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

Importance Bladder cancer is a common malignancy in women and is the fourth most
common malignancy in men. Bladder cancer ranges from unaggressive and usually …

Background Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with
heterogeneous clinical outcomes. Several molecular classifications have been proposed …

Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75–
85% of patients with bladder cancer present with a disease that is confined to the mucosa …

Urothelial carcinoma of the bladder comprises two long-recognized disease entities with
distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours …

Aim This review article summarizes the current clinical practice guidelines around disease
definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer …

Whole-genome analyses have revealed that muscle-invasive bladder cancers (MIBCs) are
heterogeneous and can be grouped into basal and luminal subtypes that are highly …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder …

Bladder cancer is the most common tumor in the urinary system, with approximately 420,000
new cases and 160,000 deaths per year. The European Organization for Research and …

Background Previous molecular subtyping for bladder carcinoma (BLCA) involved< 450
samples, with diverse classifications. Objective To identify molecular subtypes by curating a …